Should I buy or sell Neuren Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuren Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NURPF shares. View NURPF analyst ratings or view top-rated stocks .

How have NURPF shares performed in 2024?

Neuren Pharmaceuticals' stock was trading at C$16.98 on January 1st, 2024. Since then, NURPF stock has decreased by 26.2% and is now trading at C$12.53. View the best growth stocks for 2024 here .

How do I buy shares of Neuren Pharmaceuticals?

Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:NURPF

Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NURPF Stock Alerts

C$12.53

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: C$12.53
▼
C$12.53
50-Day Range: C$12.00
▼
C$14.86
52-Week Range: C$6.17
▼
C$17.21

Volume: N/A
Average Volume: 5,632 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Neuren Pharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

NURPF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NURPF Stock News Headlines

March 1, 2024 | finance.yahoo.com

Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?

February 15, 2024 | afr.com

‘Total flop’: Neuren Pharma sinks 15pc on short-seller report

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

January 23, 2024 | wsj.com

Neuren Pharmaceuticals Ltd.

December 29, 2023 | markets.businessinsider.com

Jefferies Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

December 18, 2023 | afr.com

Biotech sensation Neuren rallies to record on clinical trial results

December 18, 2023 | markets.businessinsider.com

Neuren Pharma Announces Positive Results From Phase 2 Study Of NNZ-2591 In Phelan-McDermid Syndrome

December 18, 2023 | finance.yahoo.com

Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

August 31, 2023 | markets.businessinsider.com

Wilsons Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

July 14, 2023 | afr.com

Neuren shares soar on deal to take Rett syndrome drug to the world

July 14, 2023 | markets.businessinsider.com

Wilsons Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

July 13, 2023 | fool.com.au

Why is the Neuren Pharmaceuticals share price rocketing 26% on Friday?

April 22, 2023 | msn.com

WILSONS Maintains Neuren Pharmaceuticals (ASX:NEU) Overweight Recommendation

March 17, 2023 | msn.com

ScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approval

March 12, 2023 | msn.com

Boost for ASX healthcare sector as Neuren gets US FDA approval for drug to treats Rett’s syndrome

March 3, 2023 | finance.yahoo.com

Neuren Pharmaceuticals Limited (NURPF)

January 11, 2023 | finance.yahoo.com

Breakeven Is Near for Neuren Pharmaceuticals Limited (ASX:NEU)

See More Headlines

Receive NURPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:NURPF
CUSIP: N/A
CIK: N/A
Web: www.neurenpharma.com
Phone: (139) 092-0480
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Jonathan Charles Pilcher A.C.A.
ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive Director
Ms. Lauren Frazer C.A.
CFO & Company Secretary
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
Mr. Gerry Zhao
Vice President of Corporate Development
Dr. Liza A. Squires M.D.
Chief Medical Officer

Key Competitors

View All Competitors

NURPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuren Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuren Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NURPF shares.
View NURPF analyst ratings or view top-rated stocks.
How have NURPF shares performed in 2024?: Neuren Pharmaceuticals' stock was trading at C$16.98 on January 1st, 2024. Since then, NURPF stock has decreased by 26.2% and is now trading at C$12.53.
View the best growth stocks for 2024 here.
How do I buy shares of Neuren Pharmaceuticals?: Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NURPF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial